Novo Nordisk: raises guidance following a 27 per cent rise in adjusted EBIT for the third quarter
(Il Sole 24 Ore Radiocor) - Novo Nordisk reported a 4 per cent increase in revenue and a rise of almost 30 per cent in adjusted operating profit in the third quarter, and has raised its guidance for the current financial year. The Danish pharmaceutical group, known for its weight-loss treatments, closed the July–September period with revenue of 79.19 billion Danish kroner (10.6 billion euros), up 4 per cent at constant exchange rates, and an operating profit down 9 per cent to 23 billion kroner (3.1 billion euros). Adjusted operating profit, however, rose to 31.7 billion Danish kroner, up 27 per cent on a year ago. The group has revised its full-year forecasts upwards, projecting adjusted revenue growth of between -2% and +2% at constant exchange rates, with adjusted operating profit expected to follow a similar trend (-2% to +2%). “The improved outlook is driven by higher expectations regarding sales of GLP-1-based products”, such as Wegovy, which are used in particular to treat diabetic or overweight patients.
"We are particularly pleased to note that both our US and international operations have recorded revenue growth this quarter," said Chairman and CEO Mike Doustdar – “This growth was driven by our obesity product portfolio, thanks to the continued roll-out of the Wegovy pill in the US and encouraging initial launches internationally. Our aim is to sustain this progress through rigorous execution and wider access to our medicines. We are also advancing our pipeline and preparing for the US launch of CagriSema in early 2027, subject to regulatory approval.”
fon
